[1] |
WEI Manli, LYU Linyan, ZHENG Zhiyuan, YIN Jiye, MAI Zhixiong.
Preclinical genotoxicity evaluation of xueshuantong injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1014-1018.
|
[2] |
WANG Yijin, TANG Jing, YANG Chao, XU Kai, ZHANG Mengdie, GAO Jian, WU Xiaoli, ZHANG Yue, NIU Xiaobing, JIANG Hesong, MAO Fei, ZHOU Shan, JIANG Xi, GUO Zhongying, SUN Su'an, XU Ming, XU Zongyuan, WANG Hengbing, LI Xin, FU Guangbo.
Clinical research of submucosal low-dose gemcitabine injection combined with transurethral resection of bladder tumor in the treatment of medium-high risk non-muscle invasive bladder cancer
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1044-1050.
|
[3] |
LIU Ting, CAO Zhongqiang, HE Wenjia, YUAN Xiuli, CHEN Zebin, LI Xuejuan.
One case of acute severe pancreatitis caused by pegaspargase and its etiology
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1075-1077.
|
[4] |
LIU Yi, LIU Xiaoqiang, YAO Xiao, LI Xuantang, GUO Xianhui, GENG Ying, PEI Yusheng.
Clinical compatibility of bromhexine injectable preparations
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 884-887.
|
[5] |
SHAO Bo, GUO Xiaoxin.
Review of pharmacovigilance of traditional Chinese medicine
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 741-745.
|
[6] |
ALATENG Hua, WANG Zhenxing, ZHANG Xiaomeng, SHI Wei, XI Chengwei, WANG Conghui, WANG Liqun, ZHANG Bing.
Mining and analysis of cardiac disorders risk signals based on adverse drug reaction monitoring data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 752-758.
|
[7] |
CHENG Yijing, LI Tao, LIU Junting, HUANG Guimin, ZHONG Xuli, LIN Aihua, PAN Shoudong, LI Long, BAI Dongsheng, ZHAN Xiaojun, LIU Zhenjiang, REN Wei, TAI Jun.
Safety evaluation of haemocoagulase agkistrodon for injection in children based on real world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 787-790.
|
[8] |
ZHAO Xuan, ZHENG Tingting, LI Xuemei, MAO Lu, GUO Jing, ZHANG Wei.
Adverse reaction reports of vancomycin in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 811-815.
|
[9] |
SUN Yue, HU Xinyue, LI Jing, ZHANG Wei, DING Xiaoli, ZHANG Hui, LIANG Chenggang.
Quality evaluation of desmopressin tablets and injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 632-637.
|
[10] |
DING Xiaoli, HU Xinyue, WANG Xuelei, SUN Yue, LI Jing, ZHANG Hui, Liang Chenggang, WANG Yan.
Quality evaluation of insulin glargine injections
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 644-650.
|
[11] |
SUN Xuelin, DU Jiao, TAN Qin, HU Xin, ZHANG Yatong, ZHENG Li.
Analysis of post-marketing adverse reactions of ametinib
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 683-686.
|
[12] |
LI Wenpeng, LIU Mingyu, CAO Ying, ZHOU Huziwei, WANG Shengfeng.
Supervision status and research progress of global abuse of opioids
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 513-518.
|
[13] |
LI Wenpeng, ZHOU Huziwei, ZHU Lan, WANG Shengfeng.
Applications and progress of methods for estimating opioids requirements
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 519-523.
|
[14] |
WANG Shubo, JIAO Tingting, DONG Hongliang, WANG Bailing, LI Hui.
A model for prediction of risk factors of acute kidney injury induced by voriconazole for injection based on real-world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 567-571.
|
[15] |
SUN Wu, CHEN Shuiling, ZHOU Wanyu, SHI Hang, LIU Lu, HE Yan, FU Wentao, CHU Liqun.
Two cases of uveitis caused by TNF-α inhibitor recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein for injection / etanercept for injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 457-460.
|